BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Net Debt Over TimeElevated
Percentile Rank79
3Y CAGR-3.9%
5Y CAGR+120.9%
Studio
Year-over-Year Change

Total debt minus cash and cash equivalents

3Y CAGR
-3.9%/yr
vs +87.8%/yr prior
5Y CAGR
+120.9%/yr
Recent deceleration
Acceleration
-91.7pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
52.6x
Strong expansion
Streak
1 yr
Consecutive declineElevated
PeriodValueYoY Change
2025$387.59M-47.4%
2024$736.50M+3.1%
2023$714.50M+63.6%
2022$436.69M+391.5%
2021$88.85M+1104.7%
2020$7.38M+125.0%
2019$-29.52M-184.1%
2018$35.09M+690.4%
2017$4.44M-86.0%
2016$31.62M-